



Dear LC Members,

Thank you to everyone who participated in this year's World Lymphoma Awareness Day campaign! WLAD 2018 was another resounding success. A full recap as well as reach results will be shared in the October newsletter.

The response on social media was incredible, with amazing stories of confidence shared from around the world. There were many activities happening globally, including patient conferences, hospital visits, media events, as well as awareness-raising events. See below for a sample of images from members' events:



Photos from members' WLAD events will be posted on the LC website, so please send in your photos and event details to [marketing@lymphomacoalition.org](mailto:marketing@lymphomacoalition.org). If you used any other hashtags besides **#WLAD**, or **#WorldLymphomaAwarenessDay**, please let us know to ensure all results can be tracked.

The WLAD campaign videos can be found on either the [LC Facebook page](#), or [Youtube page](#). A special acknowledgement to all the members who contributed to the videos used to promote WLAD's Small Things Build Confidence campaign. They were each viewed thousands of times and were very well received.

We look forward to receiving and sharing the full results of this year's WLAD campaign! Your contribution and support is what makes WLAD valuable.

Warmly,

Karen

## RESEARCH NEWS

- DLBCL cell of origin: What role should it play in care today? [READ MORE](#)
- Determinants of ovarian function after response-adapted therapy in patients with advanced Hodgkin's lymphoma (RATHL): a secondary analysis of a randomised phase 3 trial [READ MORE](#)
- How I treat primary mediastinal B-cell lymphoma [READ MORE](#)
- Managing neutropenia [READ MORE](#)

## RESOURCE LIBRARY

Have you looked at the valuable information contained in the Resource Library recently? A new category, Cancer-Related Brain Function, was recently added to capture information on what is often called 'chemo-brain'. [www.lymphomacoalition.org/library](http://www.lymphomacoalition.org/library)


## GLOBAL PATIENT SURVEY - SUBTYPE REPORTS

COMING SOON: Subtype reports on **cutaneous lymphoma** and **Waldenstrom's macroglobulinemia** are almost complete, and will soon be available for download on the LC website, under [Global Patient Survey 2018](#).

## ASIA PACIFIC



An enormous heartfelt thank you to all the Lymphoma Coalition Asia Pacific (LCAP) members taking part in WLAD activities. Member organisations undertook clever, creative and interesting ways to participate and be part of the campaign. A thorough overview of WLAD will be in the October newsletter.



There have been several new therapy approvals across the region. Japan recently approved brentuximab vendotin in combination of AVD for frontline treatment of Hodgkin lymphoma. Venetoclax has been approved for CLL in Australia. Obinutuzumab, Gazyva, has now been approved in both Japan and Australia for follicular lymphoma and chronic lymphocytic leukaemia (CLL). China's regulatory agency recently accepted a new drug application for tislelizumab, an investigational immune checkpoint inhibitor, for the potential treatment of patients with classical Hodgkin lymphoma who failed to respond or whose disease returned after prior therapies. Acceptance of the new drug application by the National Medical Products Administration of China (NMPA) was based on clinical and non-clinical information, including the results of a pivotal Phase 2 clinical trial. It is always great to see access increase in the region



I am currently attending the [2018 International Conference on Cancer Nursing \(ICCN 2018\)](#), which started on Sunday 23 September and goes to Wednesday 26 September, in Auckland, NZ. The ICCN provides participants with the opportunity to engage with leaders in cancer nursing from around the globe and participate in the conversations that will shape cancer nursing research and translate evidence-based cancer nursing education, practice and research into patient-centred care.

I will also be at the following meetings and would love to meet with anyone else who will also be in attendance.  
 1-4 October - UICC [World Cancer Congress](#), Kuala Lumpur, Malaysia  
 21-24 October - [Blood Conference 2018](#), Brisbane, Australia

With best regards,  
 Pru



Dear LCE Members,

September has already been a busy month and kicked off with the ECCO summit in Vienna from the 7th to the 9th. A summary article of the highlights can be found on the [LCE website here](#). Please also see the rest of the news and events section for other new stories on treatments/care and research/learning – as part of the LCE commitment to providing updates on key developments in Europe.

LCE's Advisory Committee recently met and helped review the latest plans for the Lymphoma Community Advisory Board (CAB). Information will be distributed shortly to all member organisations about how to get involved. More information about CABs can be found on the LC YouTube channel – see [Rob Camp's Prague 2018 summit presentation here](#).

Finally, Lymphoma Coalition Europe will be at the following events, so please get in touch if you're also going to be there:

- [EBMT 14th Educational Course of the Lymphoma Working Party](#) on "The Treatment of Malignant Lymphoma: State of the Art and Role of Stem Cell Transplantation" (Palma de Mallorca, Spain, 26 to 28 September)
- [EORTC Cutaneous Lymphoma Group meeting](#) (St Gallen, Switzerland, 27 to 29 September)
- [ESMO 2018 Congress](#) (Munich, Germany, 19 to 23 October)

Best wishes,  
 Jonathan

## LCE IS PROUD OF ITS MEMBERS

**Important learnings after ECCO, 7-9 September 2018**



Dr Sarolta Gundy, member of the Board of Magyar Rákellenes Liga (the Hungarian Cancer League), shared her experience and key learnings after attending the ECCO Summit that took place 7-9 September 2018 in Vienna.

What made this particular summit unique was the format. Rather than being a typical conference with scientific sessions featuring a speaker and an audience, sessions were interactive, giving everyone the chance to actively express different views, leading to an enriched debate.

## HAVE YOU VISITED THE LCE WEBSITE LATELY?

LCE is working on improving its website and has made several changes already. Look and let us know what you think and what else would be helpful for you.

Don't miss the chance to **log in to the members' area** to access the many resources available there. If you need a log in, please contact [marketing@lymphomacoalition.org](mailto:marketing@lymphomacoalition.org).

The **resource library** and **global database** provide relevant information that will keep you updated on diagnostics, treatments, survivorship, lifestyle, medical abstracts, clinical guidelines, clinical trials, and regulatory/reimbursement/funding of therapies.

[www.lymphomacoalition.org/europe](http://www.lymphomacoalition.org/europe)

## NEWS FROM EUROPE

**Towards Improving the availability of medicines in the EU**



Regulatory authorities in the European Union (EU) have set up a task force to improve the availability of medicines by mitigating potential shortages based on a two-year roadmap. The European Medicines Agency (EMA) and the Heads of Medicines Agencies (HMA) organized the task force to achieve five main objectives. These include:

1. facilitating the approval and marketing of medicines in the EU;
2. developing strategies to improve prevention and management of shortages caused by supply chain disruptions;
3. promoting best practices for shortage prevention;
4. improving information-sharing among regulatory authorities;
5. foster collaboration with stakeholders and improve communication of supply issues to citizens.

Don't miss the report! [READ IT HERE](#)

A public workshop will be held on 8-9 November to obtain stakeholder feedback on the task force's work items.

[LEARN MORE](#)

